SUPRIYA Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹206 Cr
verification pending
Revenue YoY
11%
reported change
EBITDA
₹72 Cr
latest reported figure
Source
manual review required
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Supriya Lifescience reported Q3 FY26 revenue of ₹206 crores (+11% YoY), with EBITDA at ₹72 crores (34.9% margin) and PAT at ₹50 crores (24.1% margin). The quarter underperformed management's 20% annual growth target due to post-December holiday shipment delays and new product scale-up costs in semi-regulated markets. Q4 visibility remains strong with ~₹284 crores needed to achieve full-year guidance, supported by firm order book commitments and 15-day shipment deferrals flowing into the current quarter. Management reaffirmed FY26 guidance of ~20% revenue growth with 33-35% EBITDA margins and maintained its ₹1,000 crore FY27 revenue target. Key growth catalysts include the Ambernath CDMO facility capitalization in Q4, 250-300 ton ATS-8 market capture in FY27, and 3-4 annual product launches. Risks include EU GMP audit delays for Ambernath (expected Q1 FY27), customer price acceptance for ATS-8 at $105+ levels, and absence of firm annual contracts with ATS-8 customers.
Colored figures show movement against the previous available record.
Guidance to track
- Management remains confident despite Q3's 11% growth, with larger contribution from newly launched products expected in Q4 and ~₹284 crore revenue needed to meet target.
- Management maintained guidance despite near-term pressure from new product scale-ups in semi-regulated markets, expecting normalization as products migrate to regulated markets.
- Driven by regulated market scale-up of existing portfolio, 3-4 new product launches annually, and Ambernath CDMO facility contribution starting next year.
- Commercial revenue begins Q4 FY26, with meaningful contributions expected from H2 FY27; full EBITDA positive status by Q3 FY27.
Risks flagged
- EU authority cited low manpower as reason for inability to provide immediate audit dates. Expected 3-4 months delay (Q1 FY27) could postpone regulated market traction for CDMO business.
- Market not yet accepting $105+ import price levels. Large users targeted for export are already approved; domestic market ambiguity persists. No firm annual contracts in place—only volume commitments being signed.
- Pharma validation completed in January; meaningful contribution pushed to H2 FY27 vs earlier H1 expectations. Protein project R&D completion in 3-4 months adds further timeline uncertainty.
- Environmental clearance took 2.5 years to obtain. Blueprint finalization stage; 9-12 months before any meaningful disclosure possible. Long gestation period for new capacity.
Key quotes
- We are not at all interested for taking the entire share. There should be a healthy competency. We will have only 250 to 300 tons where we will cater the customers who are choosing to have a quality material from the USFDA and EU plant.
- Whatever dip you are seeing from the historical margin numbers is predominantly because of addition of new products. When you typically introduce any new product into the portfolio, the first scale up will happen in semi-regulated market where the margins are slightly lower as compared to when it scales up in a regulated market.
- Most of the people that we are talking to are selling their finished formulations in the export market. So for us anyways the MIP is not of a very large value addition. But for us what works is that we have a fully backward integrated process and even at the current Chinese prices we are able to compete.
Research modules